Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 316

1.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655-0. doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print]

PMID:
31398540
2.

Interdisciplinary multimodality management of stage III nonsmall cell lung cancer.

Huber RM, De Ruysscher D, Hoffmann H, Reu S, Tufman A.

Eur Respir Rev. 2019 Jul 8;28(152). pii: 190024. doi: 10.1183/16000617.0024-2019. Print 2019 Jun 30. Review.

3.

Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer.

Apolle R, Appold S, Bijl HP, Blanchard P, Bussink J, Faivre-Finn C, Khalifa J, Laprie A, Lievens Y, Madani I, Ruffier A, de Ruysscher D, van Elmpt W, Troost EGC.

Acta Oncol. 2019 Jul 4:1-8. doi: 10.1080/0284186X.2019.1629017. [Epub ahead of print]

PMID:
31271079
4.

LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation.

Hartgerink D, Swinnen A, Roberge D, Nichol A, Zygmanski P, Yin FF, Deblois F, Hurkmans C, Ong CL, Bruynzeel A, Aizer A, Fiveash J, Kirckpatrick J, Guckenberger M, Andratschke N, de Ruysscher D, Popple R, Zindler J.

Acta Oncol. 2019 Jul 1:1-8. doi: 10.1080/0284186X.2019.1633016. [Epub ahead of print]

PMID:
31257960
5.

Factors determining the effect of prophylactic cranial irradiation (PCI) in patients with stage-III nonsmall cell lung cancer: exploratory subgroup analyses of the NVALT-11/DLCRG-02 phase-III study.

Witlox WJA, Ramaekers BLT, Groen HJM, Dingemans AM, Praag J, Belderbos J, van der Noort V, van Tinteren H, Joore MA, De Ruysscher DKM.

Acta Oncol. 2019 Jul 1:1-4. doi: 10.1080/0284186X.2019.1629016. [Epub ahead of print] No abstract available.

PMID:
31256737
6.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.

Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13.

PMID:
31203193
7.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D.

Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.

PMID:
31200833
8.

Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics.

van Timmeren JE, Carvalho S, Leijenaar RTH, Troost EGC, van Elmpt W, de Ruysscher D, Muratet JP, Denis F, Schimek-Jasch T, Nestle U, Jochems A, Woodruff HC, Oberije C, Lambin P.

PLoS One. 2019 Jun 3;14(6):e0217536. doi: 10.1371/journal.pone.0217536. eCollection 2019.

9.

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.

Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourgier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruysscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, Valdagni R, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium.

Radiother Oncol. 2019 May 27;138:59-67. doi: 10.1016/j.radonc.2019.04.034. [Epub ahead of print]

10.

Current status of immune checkpoint inhibition in early stage NSCLC.

Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D.

Ann Oncol. 2019 May 28. pii: mdz175. doi: 10.1093/annonc/mdz175. [Epub ahead of print]

PMID:
31143921
11.

Imaging of regional ventilation: Is CT ventilation imaging the answer? A systematic review of the validation data.

Hegi-Johnson F, de Ruysscher D, Keall P, Hendriks L, Vinogradskiy Y, Yamamoto T, Tahir B, Kipritidis J.

Radiother Oncol. 2019 Aug;137:175-185. doi: 10.1016/j.radonc.2019.03.010. Epub 2019 May 23. Review.

PMID:
31129503
12.

Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.

Schoenmaekers J, Hofman P, Bootsma G, Westenend M, de Booij M, Schreurs W, Houben R, De Ruysscher D, Dingemans AM, Hendriks LEL.

Eur J Cancer. 2019 Jul;115:88-96. doi: 10.1016/j.ejca.2019.04.017. Epub 2019 May 23.

PMID:
31129385
13.

Acylated sulfonamide adenosines as potent inhibitors of the adenylate-forming enzyme superfamily.

De Ruysscher D, Pang L, De Graef S, Nautiyal M, De Borggraeve WM, Rozenski J, Strelkov SV, Weeks SD, Van Aerschot A.

Eur J Med Chem. 2019 Jul 15;174:252-264. doi: 10.1016/j.ejmech.2019.04.045. Epub 2019 Apr 17.

PMID:
31048140
14.

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen S, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Epub 2019 Mar 15.

PMID:
31015173
15.

Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study.

De Ruysscher D, van Baardwijk A, Wanders R, Hendriks LE, Reymen B, van Empt W, Öllers MC, Bootsma G, Pitz C, van Eijsden L, Dingemans AC.

Radiother Oncol. 2019 Jun;135:141-146. doi: 10.1016/j.radonc.2019.03.009. Epub 2019 Mar 27.

PMID:
31015160
16.

Development and internal validation of a multinomial NTCP model for the severity of acute dyspnea after radiotherapy for lung cancer.

Defraene G, Schuit E, De Ruysscher D.

Radiother Oncol. 2019 Jul;136:176-184. doi: 10.1016/j.radonc.2019.03.034. Epub 2019 Apr 20.

PMID:
31015122
17.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

PMID:
30935574
18.

Population-based patterns of treatment and survival for patients with stage I and II non-small cell lung cancer aged 65-74 years and 75 years or older.

Driessen E, Detillon D, Bootsma G, De Ruysscher D, Veen E, Aarts M, Janssen-Heijnen M.

J Geriatr Oncol. 2019 Jul;10(4):547-554. doi: 10.1016/j.jgo.2019.03.001. Epub 2019 Mar 12.

PMID:
30876833
19.

Author Correction: Radiotherapy toxicity.

De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.

Nat Rev Dis Primers. 2019 Mar 4;5(1):15. doi: 10.1038/s41572-019-0073-4.

PMID:
30833595
20.

Radiotherapy toxicity.

De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.

Nat Rev Dis Primers. 2019 Feb 21;5(1):13. doi: 10.1038/s41572-019-0064-5. Review. Erratum in: Nat Rev Dis Primers. 2019 Mar 4;5(1):15.

PMID:
30792503
21.

Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?

Ramaekers B, De Ruysscher D.

J Thorac Oncol. 2019 Mar;14(3):326-327. doi: 10.1016/j.jtho.2018.12.016. No abstract available.

PMID:
30782377
22.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.

J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16.

PMID:
30780002
23.

Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.

Wink KCJ, Löck S, Rossi M, van Baardwijk A, Belderbos J, de Ruysscher D, Troost EGC.

Radiother Oncol. 2019 Feb;131:120-126. doi: 10.1016/j.radonc.2018.11.024. Epub 2018 Dec 31.

PMID:
30773178
24.

Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous.

Nieder C, Guckenberger M, Gaspar LE, Rusthoven CG, De Ruysscher D, Sahgal A, Nguyen T, Grosu AL, Mehta MP.

Radiat Oncol. 2019 Feb 15;14(1):33. doi: 10.1186/s13014-019-1237-9.

25.

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials.

Spiegelberg L, Houben R, Niemans R, de Ruysscher D, Yaromina A, Theys J, Guise CP, Smaill JB, Patterson AV, Lambin P, Dubois LJ.

Clin Transl Radiat Oncol. 2019 Jan 18;15:62-69. doi: 10.1016/j.ctro.2019.01.005. eCollection 2019 Feb.

26.

Lung-sparing intensity-modulated radiotherapy in malignant pleural mesothelioma: palliative or potentially radical?

Botticella A, De Ruysscher D.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4038-S4039. doi: 10.21037/jtd.2018.09.47. No abstract available.

27.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC.

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. No abstract available.

PMID:
30624547
28.

Prognostic Models for Patient Selection in Postoperative Radiotherapy: Ready for Use?

Billiet C, Dirix P, Meijnders P, De Ruysscher D.

J Thorac Oncol. 2018 Dec;13(12):1809-1811. doi: 10.1016/j.jtho.2018.09.018. No abstract available.

PMID:
30467043
29.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
30.

Reply to A. Addeo et al, H. Zeng et al, and C.G. Rusthoven.

De Ruysscher DK, Groen HJ.

J Clin Oncol. 2018 Oct 22:JCO1800863. doi: 10.1200/JCO.18.00863. [Epub ahead of print] No abstract available.

PMID:
30346900
31.

The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).

van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J.

Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13.

PMID:
30327236
32.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
33.

Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).

De Ruysscher D, Wanders R, Hendriks LE, van Baardwijk A, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Dingemans AC.

J Thorac Oncol. 2018 Dec;13(12):1958-1961. doi: 10.1016/j.jtho.2018.07.098. Epub 2018 Sep 22.

PMID:
30253974
34.

Radiation-Induced Lung Density Changes on CT Scan for NSCLC: No Impact of Dose-Escalation Level or Volume.

Defraene G, La Fontaine M, van Kranen S, Reymen B, Belderbos J, Sonke JJ, De Ruysscher D.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):642-650. doi: 10.1016/j.ijrobp.2018.06.038. Epub 2018 Jul 2.

PMID:
30244882
35.

External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy.

Dankers FJWM, Wijsman R, Troost EGC, Tissing-Tan CJA, Kwint MH, Belderbos J, de Ruysscher D, Hendriks LE, de Geus-Oei LF, Rodwell L, Dekker A, Monshouwer R, Hoffmann AL, Bussink J.

Radiother Oncol. 2018 Nov;129(2):249-256. doi: 10.1016/j.radonc.2018.07.021. Epub 2018 Sep 18.

PMID:
30241789
36.

Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice.

Haslett K, De Ruysscher D, Dziadziuszko R, Guckenberger M, Pechoux CL, Nestle U, Slotman B, Faivre-Finn C.

Cancer Treat Res Commun. 2018;17:18-22. doi: 10.1016/j.ctarc.2018.08.004. Epub 2018 Aug 30.

37.

Prophylactic cranial irradiation (PCI) in locally advanced non-small cell lung cancer: time for hope?

De Ruysscher DK, Groen HJ.

Oncotarget. 2018 Aug 17;9(64):32274-32275. doi: 10.18632/oncotarget.25866. eCollection 2018 Aug 17. No abstract available.

38.

Combination of radiotherapy and immune treatment: First clinical data.

De Ruysscher D.

Cancer Radiother. 2018 Oct;22(6-7):564-566. doi: 10.1016/j.canrad.2018.07.128. Epub 2018 Aug 28. Review.

PMID:
30170788
39.

4L Lymph Node Involvement in Left-Sided Lung Cancer: Unique or Not?

De Ruysscher DKM, Decaluwé H.

J Clin Oncol. 2018 Oct 10;36(29):2907-2908. doi: 10.1200/JCO.2018.79.3299. Epub 2018 Aug 27. No abstract available.

PMID:
30148657
40.

The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation.

Witlox WJA, Ramaekers BLT, Zindler JD, Eekers DBP, van Loon JGM, Hendriks LEL, Dingemans AC, De Ruysscher DKM.

Front Oncol. 2018 Jul 26;8:241. doi: 10.3389/fonc.2018.00241. eCollection 2018. Review.

41.

What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer.

de Jong EEC, Hendriks LEL, van Elmpt W, Gietema HA, Hofman PAM, De Ruysscher DKM, Dingemans AC.

Lung Cancer. 2018 Sep;123:112-115. doi: 10.1016/j.lungcan.2018.07.014. Epub 2018 Jul 18.

PMID:
30089580
42.

RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue.

Reynders K, Wauters E, Moisse M, Decaluwé H, De Leyn P, Peeters S, Lambrecht M, Nackaerts K, Dooms C, Janssens W, Vansteenkiste J, Lambrechts D, De Ruysscher D.

Radiat Oncol. 2018 Jul 17;13(1):131. doi: 10.1186/s13014-018-1075-1.

43.

Inter-observer variation of hippocampus delineation in hippocampal avoidance prophylactic cranial irradiation.

Bartel F, van Herk M, Vrenken H, Vandaele F, Sunaert S, de Jaeger K, Dollekamp NJ, Carbaat C, Lamers E, Dieleman EMT, Lievens Y, de Ruysscher D, Schagen SB, de Ruiter MB, de Munck JC, Belderbos J.

Clin Transl Oncol. 2019 Feb;21(2):178-186. doi: 10.1007/s12094-018-1903-7. Epub 2018 Jun 6.

PMID:
29876759
44.

Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions.

Hartgerink D, van der Heijden B, De Ruysscher D, Postma A, Ackermans L, Hoeben A, Anten M, Lambin P, Terhaag K, Jochems A, Dekker A, Schoenmaekers J, Hendriks L, Zindler J.

Front Oncol. 2018 May 9;8:154. doi: 10.3389/fonc.2018.00154. eCollection 2018. Review.

45.

Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.

De Ruysscher D, Dingemans AC, Praag J, Belderbos J, Tissing-Tan C, Herder J, Haitjema T, Ubbels F, Lagerwaard F, El Sharouni SY, Stigt JA, Smit E, van Tinteren H, van der Noort V, Groen HJM.

J Clin Oncol. 2018 Aug 10;36(23):2366-2377. doi: 10.1200/JCO.2017.77.5817. Epub 2018 May 22.

PMID:
29787357
46.

Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus.

Lambrecht M, Eekers DBP, Alapetite C, Burnet NG, Calugaru V, Coremans IEM, Fossati P, Høyer M, Langendijk JA, Méndez Romero A, Paulsen F, Perpar A, Renard L, de Ruysscher D, Timmermann B, Vitek P, Weber DC, van der Weide HL, Whitfield GA, Wiggenraad R, Roelofs E, Nyström PW, Troost EGC; work package 1 of the taskforce “European Particle Therapy Network” of ESTRO.

Radiother Oncol. 2018 Jul;128(1):26-36. doi: 10.1016/j.radonc.2018.05.001. Epub 2018 May 17. Review.

PMID:
29779919
47.

A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.

La Fontaine M, Vogel W, van Diessen J, van Elmpt W, Reymen B, Persson G, Westman G, De Ruysscher D, Belderbos J, Sonke JJ.

Radiother Oncol. 2018 May;127(2):259-266. doi: 10.1016/j.radonc.2018.03.020. Epub 2018 Apr 27.

PMID:
29709378
48.

Multi-center reproducibility of structural, diffusion tensor, and resting state functional magnetic resonance imaging measures.

Deprez S, de Ruiter MB, Bogaert S, Peeters R, Belderbos J, De Ruysscher D, Schagen S, Sunaert S, Pullens P, Achten E.

Neuroradiology. 2018 Jun;60(6):617-634. doi: 10.1007/s00234-018-2017-1. Epub 2018 Apr 14.

PMID:
29656321
49.

ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer.

Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePéchoux C, Van Houtte P.

Radiother Oncol. 2018 Apr;127(1):1-5. doi: 10.1016/j.radonc.2018.02.023. Epub 2018 Mar 28.

PMID:
29605476
50.

The posterior cerebellum, a new organ at risk?

Eekers DBP, In 't Ven L, Deprez S, Jacobi L, Roelofs E, Hoeben A, Lambin P, de Ruysscher D, Troost EGC.

Clin Transl Radiat Oncol. 2017 Nov 23;8:22-26. doi: 10.1016/j.ctro.2017.11.010. eCollection 2018 Jan.

Supplemental Content

Loading ...
Support Center